ArticleAnnals of medicine and surgery (2012)2026
Impact of HLA-B leader matching on clinical outcomes of haploidentical hematopoietic stem cell transplantation in adult patients with acute leukemia, a retrospective cohort study.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PTCy) has expanded donor availability for acute leukemia, yet the clinical relevance of emerging immunogenetic markers remains uncertain. This study investigated whether donor-recipient human leukocyte antigen (HLA)-B leader matching influences transplantation outcomes in adults with acute leukemia undergoing haplo-HSCT. Methods: This retrospective analytical cohort included consecutive adults (18-65 years) with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) who underwent their first haplo-HSCT at one of the most prominent referral hospitals between January 2008 and December 2022. HLA-B leader status was determined by exon 1 sequencing and classified as matched or mismatched between donor and recipient. Outcomes included overall survival (OS), disease-free survival, relapse incidence (RI), non-relapse mortality (NRM), engraftment, acute and chronic graft-versus-host disease (GVHD), and GVHD-free/relapse-free survival (GRFS). Kaplan-Meier methods, Cox regression, and competing-risk models were applied. Results: A total of 140 patients were analyzed (AML 67.9% and ALL 32.1%); 106 (75.7%) were HLA-B leader matched and 34 (24.3%) mismatched, with a median follow-up of 68 months among survivors. HLA-B leader mismatching was not associated with OS [multivariable hazard ratio (HR) = 1.02, 95% confidence interval (CI): 0.65-1.60; Conclusion: In adults with acute leukemia undergoing PTCy-based haplo-HSCT, HLA-B leader matching was not associated with survival or GVHD. However, the observed trend toward lower relapse with leader mismatching, together with the protective association between acute GVHD and relapse, suggests a potential graft-versus-leukemia signal that warrants validation in larger cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.